EGFR and non-small cell lung carcinoma: Afatinib (an irreversible HER-family blocker), dacomitinib (an irreversible TKI of EGFR, HER2 and HER4) and icotinib (an EGFR TKI) have shown activity in EGFR mutation-positive NSCLC [11–16].